search
Back to results

Study of Postoperative Analgesia in Bunionectomy

Primary Purpose

Bunion, Hallux Valgus

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
SKY0402
Placebo
Sponsored by
Pacira Pharmaceuticals, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bunion focused on measuring Bunion, Bunionectomy, Osteotomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years at the Screening visit
  • Scheduled to undergo primary unilateral first metatarsal osteotomy without hammertoe
  • Female subjects must be surgically sterile or at least two years menopausal, or using an acceptable method of birth control. If of childbearing potential, have a documented negative blood or urine pregnancy test within 24 hours before surgery
  • Clinical laboratory values less than or equal to twice the upper limit of normal or, if abnormal, deemed not clinically significant per the Investigator
  • Ability to provide informed consent, adhere to the study visit schedule and complete all study assessments

Exclusion Criteria:

  • Currently pregnant, nursing, or planning to become pregnant during the study or within one month after study drug administration
  • Chronic user of analgesic medications, including taking opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week
  • Use of any non-steroidal anti-inflammatory drug (NSAID) including selective COX-2 inhibitor within three days of surgery
  • Use of acetaminophen within 24 hours of surgery
  • Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) within three days of surgery
  • Current use of systemic glucocorticosteroids or use of systemic glucocorticoids within one month of enrollment into this study
  • Peripheral neuropathy including diabetic neuropathy, chemotherapy-induced neuropathy, HIV neuropathy
  • History of hepatitis
  • History of, suspected, or known addiction to or abuse of drugs or alcohol within the past two years
  • Failure to pass urine drug screen
  • Current evidence of alcohol abuse (greater than 4 units of alcohol per day: 1 unit = ½ pint of beer, 1 glass of wine or 1 oz. of spirits)
  • Evidence of peripheral ischemic disease
  • Type I or Type II diabetes
  • Current acute or chronic medical or major psychiatric disease that, in the opinion of the Investigator, would interfere with the evaluation of study drug efficacy or safety
  • Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • Administration of an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
  • Previous participation in a SKY0402 study
  • Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures
  • Current painful physical conditions or concurrent surgery other than bunionectomy that may require analgesic treatment (such as NSAID or opioid) in the postoperative period for pain that is not strictly related to the bunionectomy procedure and may confound the postoperative assessments

Sites / Locations

  • Premier Research Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sky0402

Placebo

Arm Description

Injection of Study Drug

Injection of study drug

Outcomes

Primary Outcome Measures

Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
The AUC of the NRS-R pain intensity scores from time 0 through 24 hours The subject was to rest for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

Secondary Outcome Measures

Adverse Event Profile
Participants with an Adverse Event through 72 hours or a Serious Adverse Event through 30 days

Full Information

First Posted
April 28, 2009
Last Updated
July 2, 2013
Sponsor
Pacira Pharmaceuticals, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT00890682
Brief Title
Study of Postoperative Analgesia in Bunionectomy
Official Title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (Bunionectomy)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
November 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pacira Pharmaceuticals, Inc

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
After undergoing bunion surgery, patients are given a pain medicine injection that may last for up to several days or a placebo. Their pain and pain medicine use is then monitored.
Detailed Description
Following drug study administration, safety and efficacy assessments were conducted

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bunion, Hallux Valgus
Keywords
Bunion, Bunionectomy, Osteotomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
193 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sky0402
Arm Type
Experimental
Arm Description
Injection of Study Drug
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Injection of study drug
Intervention Type
Drug
Intervention Name(s)
SKY0402
Other Intervention Name(s)
EXPAREL
Intervention Description
Local infiltration of 8cc SKY0402
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
saline 0.9%
Intervention Description
Local infiltration of 8cc Placebo
Primary Outcome Measure Information:
Title
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
Description
The AUC of the NRS-R pain intensity scores from time 0 through 24 hours The subject was to rest for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"
Time Frame
0-24 hours
Secondary Outcome Measure Information:
Title
Adverse Event Profile
Description
Participants with an Adverse Event through 72 hours or a Serious Adverse Event through 30 days
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at the Screening visit Scheduled to undergo primary unilateral first metatarsal osteotomy without hammertoe Female subjects must be surgically sterile or at least two years menopausal, or using an acceptable method of birth control. If of childbearing potential, have a documented negative blood or urine pregnancy test within 24 hours before surgery Clinical laboratory values less than or equal to twice the upper limit of normal or, if abnormal, deemed not clinically significant per the Investigator Ability to provide informed consent, adhere to the study visit schedule and complete all study assessments Exclusion Criteria: Currently pregnant, nursing, or planning to become pregnant during the study or within one month after study drug administration Chronic user of analgesic medications, including taking opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week Use of any non-steroidal anti-inflammatory drug (NSAID) including selective COX-2 inhibitor within three days of surgery Use of acetaminophen within 24 hours of surgery Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) within three days of surgery Current use of systemic glucocorticosteroids or use of systemic glucocorticoids within one month of enrollment into this study Peripheral neuropathy including diabetic neuropathy, chemotherapy-induced neuropathy, HIV neuropathy History of hepatitis History of, suspected, or known addiction to or abuse of drugs or alcohol within the past two years Failure to pass urine drug screen Current evidence of alcohol abuse (greater than 4 units of alcohol per day: 1 unit = ½ pint of beer, 1 glass of wine or 1 oz. of spirits) Evidence of peripheral ischemic disease Type I or Type II diabetes Current acute or chronic medical or major psychiatric disease that, in the opinion of the Investigator, would interfere with the evaluation of study drug efficacy or safety Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix Administration of an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study Previous participation in a SKY0402 study Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures Current painful physical conditions or concurrent surgery other than bunionectomy that may require analgesic treatment (such as NSAID or opioid) in the postoperative period for pain that is not strictly related to the bunionectomy procedure and may confound the postoperative assessments
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Daniels, DO
Organizational Affiliation
Premier Research Group Clinical Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Premier Research Group
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22900785
Citation
Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3.
Results Reference
derived
PubMed Identifier
21842428
Citation
Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12.
Results Reference
derived

Learn more about this trial

Study of Postoperative Analgesia in Bunionectomy

We'll reach out to this number within 24 hrs